Transgenic Mice as a Model for Cancer Therapy
Author Information
Author(s): H Thomas, AM Hanby, R-A Smith, P Hagger, K Patel, B Raikundalia, RS Camplejohn, FR Balkwill
Primary Institution: ICRF Biological Therapies Laboratory
Hypothesis
Can transgenic mice carrying the activated rat c-neu oncogene serve as a model for evaluating cancer therapies?
Conclusion
The study found that the transgenic mice developed a variety of tumors that resemble human cancers, suggesting their potential for evaluating novel therapies.
Supporting Evidence
- 86 of 268 transgene-positive mice developed 93 diverse tumors.
- The cumulative incidence of breast tumors at 24 months was 18%.
- Breast tumors showed a range of architectural patterns resembling human cancers.
- Transgene positivity declined with successive generations.
- Virgin mice had fewer mammary tumors than those with two litters.
Takeaway
Scientists created special mice that can get different types of cancer to help test new medicines for treating cancer.
Methodology
Transgenic mice were backcrossed to BALB/c mice, and tumor development was monitored over several generations.
Limitations
Further genetic and environmental manipulations are needed to increase tumor incidence and decrease age of onset.
Participant Demographics
Transgenic female mice of mixed genetic backgrounds were used.
Statistical Information
P-Value
0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website